Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hannah Rinks

Nurse Practitioner Cookeville, TN Nurse Practitioner

NPI 1376042317 CMS profile 11218909

222 W 4Th St, Cookeville, TN 38501

Open in the dashboard

General payments

$3,121

77 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Rinks of Cookeville, TN is reported in the CMS Open Payments database as having received $3,121 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $326 15
2024 General $529 21
2023 General $1,512 22
2022 General $667 15
2021 General $87 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Rinks
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Hannah Rinks were reported at $326. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Hannah Rinks Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $87 $135 $40–$426 $132
2022 $667 $152 $48–$470 $149
2023 $1,512 $166 $54–$529 $160
2024 $529 $173 $55–$556 $164
2025 $326 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Silk Road Medical, Inc. $1,297 9 payments
  2. W. L. Gore & Associates, Inc. $782 28 payments
  3. Boston Scientific Corporation $352 13 payments
  4. Medtronic, Inc. $196 7 payments
  5. Shockwave Medical, Inc $165 8 payments
  6. Abiomed $126 4 payments
  7. Intuitive Surgical, Inc. $57 1 payment
  8. Cardiovascular Systems Inc. $26 1 payment
  9. Terumo Medical Corporation $24 1 payment
  10. Abbott Laboratories $22 1 payment
  11. Other $75 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,744 76 payments
  2. Travel and Lodging $377 1 payment
Products named General payments · program years 2021–2025
  1. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,297 9 payments
  2. ENROUTE Transcarotid Stent $1,297 9 payments
  3. GORE EXCLUDER AAA Endoprosthesis $533 20 payments
  4. GORE TAG Conformable Thoracic Endoprosthesis $172 1 payment
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $165 8 payments
  6. Impella $102 3 payments
  7. WATCHMAN FLX $68 1 payment
  8. Abre $63 1 payment
  9. Da Vinci Surgical System $57 1 payment
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $54 3 payments
  11. Other $591 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

796

Median for Nurse Practitioner: 389

Drug cost

$107,138

Median for Nurse Practitioner: $21,885

Branded share of claims

65.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $41,752
Xarelto Rivaroxaban Brand 42 $41,224
Brilinta Ticagrelor Brand 29 $14,114
Clopidogrel Clopidogrel Bisulfate Brand 355 $4,072
Prasugrel Hcl Generic 32 $3,080
Cilostazol Generic 71 $1,384
Atorvastatin Calcium Generic 35 $533
Metoprolol Succinate Generic 36 $267
Gabapentin Generic 19 $121
Rosuvastatin Calcium Generic 20 $112

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$8,968

Medicare's payments for the services billed

Medicare patients

129

Average age 77

Services billed

158

53 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 57%
Diabetes 50%
Chronic kidney disease 41%
COPD 41%
Heart failure 34%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record